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S8 Journal of Thoracic Oncology Vol. 11 No. 2SWhile we have shown that these urinary metabolites
are risk biomarkers for lung cancer in these studies, they
are not fully predictive. This is because these biomarkers
are mainly measuring exposure but do not take into ac-
count the critical metabolic activation step leading to the
formation of DNA adducts which cause the multiple
mutations observed in lung cancer. Quantitation of DNA
adducts is challenging because of their low levels, typi-
cally less than 1 adduct per 107 normal bases, and the
small amounts of DNA available for studies in living
humans. To address this question, we are developing high
resolution mass spectrometric methods for quantifying
oral cell DNA adducts as a surrogate for DNA adduct
formation in the lung. In one recent study, we found
remarkably high levels of DNA adducts of tobacco-
speciﬁc compounds in in the oral mucosa cells of smokers
compared to non-smokers. We are also able to quantify
formaldehyde-DNA adducts in oral mucosa cells. As mass
spectrometric methods for analysis of carcinogen-DNA
adducts become increasingly more sensitive and speciﬁc,
it appears likely that quantitation of a panel of tobacco
carcinogen DNA adducts in smokers, leading to identiﬁ-
cation of susceptible individuals, may be feasible.
Targeting PD1 and PDL1 in lung cancer
treatment: Where are we now?Roy S. Herbst Yale Cancer Center,
New Haven, CTThe therapy for advanced non-small cell lung cancer has
improved dramatically in recent years. We have moved
from an era of Cisplatin-based chemotherapy to the use
of targeted therapy, immunotherapy, and their combi-
nations. Of equal importance is the evolution of more
personalized tissue-based therapy used to guide choice.
This lecture will chronicle the 10+ year history of the
development of biopsy-based treatments for lung cancer,
evolving from the initial BATTLE trials to the Umbrella
and Master Protocols of today. The dawn of immuno-
therapy will be discussed along with efforts designed to
administer it in a more targeted way with the develop-
ment of novel biomarker and combinations.
Beyond monotherapy: Integrating
immunotherapy into current
treatment regimensKaren L. Kelly University of California, Davis,
Sacramento, CAImmunotherapy strategies targeting immune checkpoints
including PD-1, PDL-1, and CTLA-4, have garneredsubstantial enthusiasm after demonstrating clinical ac-
tivity in a broad spectrum of tumor types. In metastatic
non-small cell lung cancer (NSCLC) two randomizedphase
III trials have convincingly shown an overall survival
beneﬁt in patients receiving nivolumab in the second line
setting. The ﬁrst trial conducted in patients with squa-
mous cell histology randomized 272 patients to receive
nivolumab or docetaxel (1). The HR for OS was 0.59 (95%
CI 0.44-0.79; p<0.001). The median survival times were
9.2 months for nivoulmab and 6.0 months for docetaxel.
In the second trial performed in 582 patients with
nonsquamous cell histology nivolumab was again shown
to be superior to docetaxel with an OS HR 0.73 (95% CI
0.59-0.88; p¼0.002) and a median survival time of 12.2
months for nivoulmab and 9.4 months for docetaxel (2).
Two additional randomized trials comparing docetaxel
to pembrolizumab (anti PD-L inhibitor) or atezolizumab
(anti PDL-1 inhibitor) have completed accrual and are
likely to favor the immunotherapy arm. The efﬁcacy and
mild, non-overlapping toxicity proﬁle of immune
checkpoint inhibitors make them an ideal partner to
combine with systemic agents such as cytotoxic
chemotherapy, molecularly targeted agents and other
immune therapies in an effort to further prolong
survival for patients with advanced lung cancer.
Combinations with cytotoxic chemotherapy. The ratio-
nale for evaluating chemotherapy with immune check-
point inhibitors include: 1) tumor cell death from
conventional therapies releases neo-antigens into the
microenvironment leading to immune activation, the
recruitment of cytotoxic T cells and additional tumor cell
death 2) several cytotoxic chemotherapy agents have
been shown to promote “immunogenic cell death” and
3) systemic therapies can inﬂuence the immune micro-
environment, i.e. gemcitabine can suppress negative
immune regulators (3-5). In preclinical experiments,
chemotherapy plus PD-1, PDL-1 or CTLA-4 inhibitors
have demonstrated enhanced antitumor activity leading
to their evaluation in patients. Several phase I clinical
trials combining immune checkpoint inhibitors with a
variety of platinum based doublet have shown the
combination regimens are safe and tolerable (6-8).
Objective response rates and progression free survival
were favorable. As a result, numerous randomized
phase III trials comparing platinum doublets with or
without an immune checkpoint inhibitor are underway.
Combinations with molecularly targeted agents. The
rationale for pursuing these dual regimens is also based
on the release of neoantigens that occurs upon cell death
with effective targeted therapy (3,4). In addition
targeted therapies have been shown to remodel the
immune microenviroment. For example EGFR TKIs can
decrease PD-L1 expression and lead to tumor
regression in EGRF driven animal models (9). One
